Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Site-Targeted Drug Delivery Systems: Polymeric Carriers01:24

Site-Targeted Drug Delivery Systems: Polymeric Carriers

160
Polymeric carriers enhance targeted drug delivery by increasing efficacy while minimizing off-target effects. These carriers comprise a biodegradable polymeric backbone integrated with functional elements that enable targeting, improve physicochemical properties, and regulate drug release.Targeting MechanismsThe targeting ability of polymeric carriers is mediated by a homing device, which is a molecular recognition component designed to selectively bind to specific tissues or cells. Monoclonal...
160
Modified-Release Drug Delivery Systems: Stimuli-Activated01:30

Modified-Release Drug Delivery Systems: Stimuli-Activated

177
Stimuli-activated drug delivery systems are designed to release drugs in response to specific physical, chemical, or biological stimuli. These systems often utilize hydrogels—three-dimensional, hydrophilic polymer networks capable of swelling in aqueous environments and retaining significant fluid volumes. Upon exposure to particular stimuli, these hydrogels undergo structural transitions that allow the embedded drug to be released. Due to this adaptive behavior, such systems are also...
177
Drug Delivery Systems: Different Types01:27

Drug Delivery Systems: Different Types

406
Conventional oral drug products, termed immediate-release (IR) formulations, are engineered to promptly release their active pharmaceutical ingredient (API) upon ingestion, typically in tablets or capsules. This rapid release often results in swift drug absorption and consequent pharmacodynamic effects, although the timing and intensity can vary depending on the drug's properties. Prodrugs within these formulations require metabolic conversion to activate their pharmacodynamic effects,...
406
Modified-Release Drug Delivery Systems: Site-Targeted01:24

Modified-Release Drug Delivery Systems: Site-Targeted

164
Site-targeted drug delivery systems enhance therapeutic efficacy while minimizing systemic toxicity and treatment costs. Unlike conventional methods, these systems ensure precise drug delivery, improving bioavailability and reducing side effects. Targeted drug delivery is classified into three levels. First-order targeting directs drugs to the capillary beds of specific organs or tissues. Second-order targets specific cell types, such as tumor cells, using receptor-mediated interactions.
164
Modified-Release Drug Delivery Systems: Rate-Programmed II01:19

Modified-Release Drug Delivery Systems: Rate-Programmed II

137
Rate-programmed drug delivery systems release drugs in a controlled manner to maintain therapeutic levels. Three main designs include reservoir, matrix, and hybrid systems.Reservoir systems consist of a drug core enclosed within a membrane that controls drug release. In non-swelling reservoir systems, polymers like ethyl cellulose or polymethacrylates are used. These do not hydrate in aqueous media and control release through membrane thickness, porosity, or insolubility. This type includes...
137
Modified-Release Drug Delivery Systems: Overview01:19

Modified-Release Drug Delivery Systems: Overview

236
Modified-release dosage forms are designed to address the limitations of drugs with short biological half-lives. These forms maintain stable therapeutic drug concentrations over extended periods, reducing the need for frequent dosing. A consistent drug level helps minimize peak-trough fluctuations, which can reduce adverse effects, lower the risk of drug resistance, and improve overall treatment effectiveness.One common type of modified-release form is the extended-release (ER) formulation. ER...
236

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

BAG3: a new therapeutic target of human cancers?

Histology and histopathology·2012
Same author

Z-Selectivity in olefin metathesis with chelated Ru catalysts: computational studies of mechanism and selectivity.

Journal of the American Chemical Society·2012
Same author

Complications after pancreaticoduodenectomy for pancreatic cancer: a retrospective study.

International surgery·2012
Same author

[Inhibitory effect of valproic acid on xenografted Kasumi-1 tumor growth in nude mouse and its mechanism].

Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi·2012
Same author

[Foix syndrome secondary to chemotherapy of acute nonlymphocytic leukemia: a case report and review of the literature].

Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi·2012
Same author

Effect of resistant starch film properties on the colon-targeting release of drug from coated pellets.

Journal of controlled release : official journal of the Controlled Release Society·2011

Related Experiment Video

Updated: May 2, 2026

Production of Near-Infrared Sensitive, Core-Shell Vaccine Delivery Platform
06:27

Production of Near-Infrared Sensitive, Core-Shell Vaccine Delivery Platform

Published on: October 20, 2020

4.2K

Novel smart yolk/shell polymer microspheres as a multiply responsive cargo delivery system.

Pengcheng Du1, Peng Liu

  • 1State Key Laboratory of Applied Organic Chemistry and Key Laboratory of Nonferrous Metal Chemistry and Resources Utilization of Gansu Province, College of Chemistry and Chemical Engineering, Lanzhou University , Lanzhou 730000, China.

Langmuir : the ACS Journal of Surfaces and Colloids
|February 28, 2014
PubMed
Summary

Researchers developed smart polymer microspheres for targeted cancer drug delivery. These responsive drug delivery systems control drug release in tumor environments, offering a promising new therapy with low toxicity.

More Related Videos

Alternating Magnetic Field-Responsive Hybrid Gelatin Microgels for Controlled Drug Release
09:11

Alternating Magnetic Field-Responsive Hybrid Gelatin Microgels for Controlled Drug Release

Published on: February 13, 2016

9.3K
Intra-lymph Node Injection of Biodegradable Polymer Particles
09:06

Intra-lymph Node Injection of Biodegradable Polymer Particles

Published on: January 2, 2014

17.0K

Related Experiment Videos

Last Updated: May 2, 2026

Production of Near-Infrared Sensitive, Core-Shell Vaccine Delivery Platform
06:27

Production of Near-Infrared Sensitive, Core-Shell Vaccine Delivery Platform

Published on: October 20, 2020

4.2K
Alternating Magnetic Field-Responsive Hybrid Gelatin Microgels for Controlled Drug Release
09:11

Alternating Magnetic Field-Responsive Hybrid Gelatin Microgels for Controlled Drug Release

Published on: February 13, 2016

9.3K
Intra-lymph Node Injection of Biodegradable Polymer Particles
09:06

Intra-lymph Node Injection of Biodegradable Polymer Particles

Published on: January 2, 2014

17.0K

Area of Science:

  • Materials Science
  • Polymer Chemistry
  • Nanotechnology

Background:

  • Developing effective drug delivery systems (DDS) is crucial for targeted cancer therapy.
  • Stimuli-responsive polymers offer potential for controlled drug release.
  • Yolk/shell structures can enhance drug loading and release profiles.

Purpose of the Study:

  • To fabricate novel dually thermo- and pH-responsive yolk/shell polymer microspheres for controlled anticancer drug delivery.
  • To investigate the drug release characteristics in response to tumor microenvironment conditions.
  • To evaluate the in vitro cytotoxicity of the developed DDS.

Main Methods:

  • Fabrication of yolk/shell polymer microspheres using two-stage distillation precipitation polymerization and seed precipitation polymerization.
  • Characterization of the microspheres' responsiveness to pH and temperature.
  • In vitro drug release studies of doxorubicin hydrochloride (DOX) at different pH values and temperatures.
  • Cytotoxicity assessment using HepG2 cells.

Main Results:

  • Successfully synthesized dually thermo- and pH-responsive yolk/shell polymer microspheres.
  • Demonstrated pH-triggered "on-off" drug release, with enhanced release at lower pH mimicking tumor environments.
  • Achieved high drug loading capacity for doxorubicin hydrochloride (DOX).
  • Exhibited very low in vitro cytotoxicity on HepG2 cells.

Conclusions:

  • The developed yolk/shell polymer microspheres function as an effective drug delivery system for controlled anticancer drug release.
  • The smart "valve" mechanism of the polymer shells enables precise, tumor-environment-responsive drug delivery.
  • These findings suggest promising potential for the developed DDS in advanced tumor therapy.